Liquidia vs Amgen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Liquidia Technologies Inc (LQDA)

Q3 202629 Jun – 2 Oct 2026

▲2▼2

Yutrepia Launch Booms, Then Patent Ruling Threatens Key Market

Yutrepia launch exceeds expectations Yutrepia's launch delivered strong growth: annualized revenue hit about $520 million, with $300 million in first-half sales, over 5,000 patients started, and four straight profitable quarters. Analysts raised estimates as the stock more than doubled.
This is the main positive force behind the stock's rise during the period.
Patent ruling threatens PH-ILD market A Delaware court ruled that Yutrepia infringes a United Therapeutics patent covering PH-ILD use, threatening a key market and future sales. This legal setback reversed earlier momentum and weighed heavily on the stock.
This is the major negative event that changed the stock's trajectory.
Analyst downgrades and price target cuts Wells Fargo, BTIG, and Raymond James downgraded the stock and sharply cut price targets following the patent ruling, reflecting reduced confidence in future sales and earnings.
These downgrades amplified the negative impact of the patent ruling on the stock price.
FDA Fast Track for Raynaud's The FDA granted Fast Track status for Yutrepia in scleroderma-related Raynaud's phenomenon, a smaller, early-stage opportunity that partly offsets the negative patent news.
This is a new positive development that provides some counterbalance to the negative drivers.

September 20265 Aug – 2 Oct 2026

▲2▼2

Liquidia's Yutrepia Boom Meets Patent Setback

Yutrepia sales surge Yutrepia, Liquidia's lung drug, sold about $300 million in the first half of 2026, with over 5,000 patients started and a fourth straight profitable quarter. This rapid sales growth is the main reason the stock had more than doubled this year.
It shows the core business is growing fast, which is the main force pushing LQDA up.
Patent loss threatens key use A Delaware court ruled Yutrepia infringes a United Therapeutics patent covering its use for PH-ILD, a lung condition. If the ruling stands, Yutrepia could be restricted from that market, cutting future sales and profits.
This is the biggest new negative force, directly threatening a major part of Yutrepia's market.
Downgrades slash price targets Wells Fargo downgraded Liquidia to Equal Weight and cut its price target to $30 from $108, with BTIG and Raymond James also downgrading. These cuts reflect lost confidence in future growth and weigh on the stock.
It shows how the patent ruling changed analyst views, adding selling pressure on LQDA.
Fast Track for new use The FDA gave Fast Track status to Yutrepia for Raynaud's phenomenon linked to scleroderma, a new potential market. This speeds development and could add future sales, though it is still early and small compared to the patent risk.
It is a new positive regulatory step that could expand Yutrepia's label, offering a counterweight to the patent setback.

Latest5 Aug – 2 Oct 2026

▲2▼2

Liquidia's Yutrepia Boom Meets Patent Setback

Yutrepia sales surge Yutrepia, Liquidia's lung drug, sold about $300 million in the first half of 2026, with over 5,000 patients started and a fourth straight profitable quarter. This rapid sales growth is the main reason the stock had more than doubled this year.
It shows the core business is growing fast, which is the main force pushing LQDA up.
Patent loss threatens key use A Delaware court ruled Yutrepia infringes a United Therapeutics patent covering its use for PH-ILD, a lung condition. If the ruling stands, Yutrepia could be restricted from that market, cutting future sales and profits.
This is the biggest new negative force, directly threatening a major part of Yutrepia's market.
Downgrades slash price targets Wells Fargo downgraded Liquidia to Equal Weight and cut its price target to $30 from $108, with BTIG and Raymond James also downgrading. These cuts reflect lost confidence in future growth and weigh on the stock.
It shows how the patent ruling changed analyst views, adding selling pressure on LQDA.
Fast Track for new use The FDA gave Fast Track status to Yutrepia for Raynaud's phenomenon linked to scleroderma, a new potential market. This speeds development and could add future sales, though it is still early and small compared to the patent risk.
It is a new positive regulatory step that could expand Yutrepia's label, offering a counterweight to the patent setback.

July 202629 Jun – 22 Jul 2026

▲4

Yutrepia Sales Soar, Patent Ruling Favors Liquidia

Yutrepia launch drives rapid revenue growth and profitability Liquidia scaled annualized revenue from near zero to about $520 million in three quarters, with Q1 2026 sales of $130 million and a third straight profitable quarter. This shows strong demand and execution, pushing the stock up.
This is the core fundamental driver of LQDA's price surge.
Judge criticizes United Therapeutics in patent dispute A judge criticized United Therapeutics for altering an interrogatory response, calling it deceptive. This legal development reduces the risk of an adverse ruling that could remove Yutrepia from the market, boosting investor confidence.
This is a new legal development that directly affects the key risk overhang on the stock.
Yutrepia adoption metrics show strong market penetration Over 4,500 prescriptions, 3,750 patients, and nearly 1,000 prescribing physicians indicate robust adoption. 75% of new starts are treatment-naive, meaning the market is expanding, not just stealing share. This supports future growth expectations.
These metrics demonstrate the strength of the launch and its potential for continued growth.
Analyst and investor optimism, with price target increases Laughing Water Capital called the launch 'fantastic' and believes the worst-case patent outcome is off the table. The Zacks consensus EPS estimate for 2026 rose to $3.02 from $1.50, and the stock has surged over 130% year to date, reflecting growing confidence.
This shows third-party validation and improving earnings expectations, which drive stock price.

29 Jun – 22 Jul 2026

▲4

Yutrepia Sales Soar, Patent Ruling Favors Liquidia

Yutrepia launch drives rapid revenue growth and profitability Liquidia scaled annualized revenue from near zero to about $520 million in three quarters, with Q1 2026 sales of $130 million and a third straight profitable quarter. This shows strong demand and execution, pushing the stock up.
This is the core fundamental driver of LQDA's price surge.
Judge criticizes United Therapeutics in patent dispute A judge criticized United Therapeutics for altering an interrogatory response, calling it deceptive. This legal development reduces the risk of an adverse ruling that could remove Yutrepia from the market, boosting investor confidence.
This is a new legal development that directly affects the key risk overhang on the stock.
Yutrepia adoption metrics show strong market penetration Over 4,500 prescriptions, 3,750 patients, and nearly 1,000 prescribing physicians indicate robust adoption. 75% of new starts are treatment-naive, meaning the market is expanding, not just stealing share. This supports future growth expectations.
These metrics demonstrate the strength of the launch and its potential for continued growth.
Analyst and investor optimism, with price target increases Laughing Water Capital called the launch 'fantastic' and believes the worst-case patent outcome is off the table. The Zacks consensus EPS estimate for 2026 rose to $3.02 from $1.50, and the stock has surged over 130% year to date, reflecting growing confidence.
This shows third-party validation and improving earnings expectations, which drive stock price.

Amgen Inc (AMGN)

Q3 20268 Jul – 14 Sep 2026

▲2▼2

Amgen Q3: Pelacarsen Blow Sinks Shares, Recalls and Rival Threats Weigh

Pelacarsen failure casts doubt on Amgen's olpasiran Novartis' heart drug pelacarsen failed, and because Amgen's similar olpasiran works the same way, investors feared it could fail too. Shares fell about 10% and BMO downgraded the stock.
This was the single most severe event of the quarter, directly sinking the share price.
Court blocks Colorado's 70% Enbrel price cap A court blocked Colorado's 70% price cap on Enbrel, reducing regulatory risk for Amgen's biggest drug. This removes a threat that could have slashed revenue from a key product.
A major legal win that eased a key overhang on the stock.
Q2 beat and raised guidance, key products grow 26% Amgen's Q2 earnings and revenue beat estimates, and the company raised its full-year guidance. Six key products grew 26%, showing the new drug lineup is driving growth.
Strong financial results and raised outlook support the stock.
Recalls, competition, pipeline setback, cyberattack Corlanor and Sensipar recalls raised quality concerns. Merck's cheaper oral PCSK9 threatens Repatha, Sotyktu may erode Otezla, AMG 513 was discontinued, and a cyberattack triggered lawsuits.
Multiple negative events that weighed on sentiment and future growth prospects.

September 20267 Sep – 14 Sep 2026

▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.
This is the main new force driving AMGN down this period.
BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.
Analyst downgrade is a direct new negative catalyst for the stock.
IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.
A major positive pipeline win that offsets some of the Lp(a) pessimism.
FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.
Regulatory win that improves commercial practicality of a growth drug.

Latest7 Sep – 14 Sep 2026

▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.
This is the main new force driving AMGN down this period.
BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.
Analyst downgrade is a direct new negative catalyst for the stock.
IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.
A major positive pipeline win that offsets some of the Lp(a) pessimism.
FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.
Regulatory win that improves commercial practicality of a growth drug.

August 202629 Jul – 3 Sep 2026

▲2▼2

Amgen beats Q2, raises guidance, but obesity setback and cyberattack weigh

Q2 earnings beat and guidance raise Amgen reported Q2 adjusted EPS of $6.29 and revenue of $10.05B, beating estimates, and raised its 2026 guidance. Six key growth products grew 26%, reducing reliance on older drugs.
This is a new positive fundamental development that directly supports the stock.
Repatha and Tezspire clinical wins Repatha cut death risk by 20% in a major heart trial, and Tezspire met all goals in an eosinophilic esophagitis study. These results lifted shares to a 52-week high and prompted analyst target hikes.
New clinical data and analyst reactions are key drivers of the stock's move this period.
Obesity drug AMG 513 discontinued Amgen discontinued its obesity drug AMG 513, leaving MariTide trailing Eli Lilly and Novo Nordisk in the lucrative obesity market. This raises concerns about Amgen's competitive position.
This is a new negative event that affects future growth prospects.
Cyberattack and drug-price pressure A July cyberattack exposed patient and proprietary data, triggering a class action investigation. Also, a looming US drug-price agreement with mid-sized biotechs could pressure Medicaid revenue.
These are new risk factors that emerged during the period and could weigh on the stock.

8 Aug – 3 Sep 2026

▲3▼1

Amgen Hits 52-Week High on Q2 Beat, Repatha and Tezspire Wins

Repatha Cuts Death Risk 20% in Major Heart Trial Amgen's Repatha reduced death risk by 20% in high-risk heart patients in the VESALIUS-CV trial, a major win for its biggest growth drug. This strengthens the case for wider use and future sales, supporting a higher stock price.
This is a new, high-impact clinical win that directly boosts confidence in Amgen's key growth driver.
Tezspire Meets All Goals in Eosinophilic Esophagitis Trial Amgen and AstraZeneca's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, a chronic throat condition with few good treatments. This opens a new market and adds to Tezspire's growth story, lifting investor optimism.
New positive trial results expand a key product's potential, a fresh catalyst for the stock.
US Drug Price Agreement with Mid-Sized Biotechs Looms The Trump administration is expected to announce a drug price agreement with mid-sized biotech firms, and Amgen was among companies urged to cut US prices. If Amgen is included, lower Medicaid prices could pressure revenue and weigh on the stock.
This is a new regulatory risk that could directly affect Amgen's pricing and profits.
Analyst Fair Value and Price Targets Raised After Q2 Beat Following Amgen's strong Q2 results, analysts raised their fair value estimate to about $372 and several price targets into the $450 range, citing broad franchise strength. Higher targets can pull the stock up as investors adjust expectations.
This is a new analyst reaction that reflects upgraded expectations and can influence the stock price.

29 Jul – 6 Aug 2026

▲2▼2

Amgen Q2 Beat and Guidance Raise Outweigh Data Breach and Obesity Setback

Q2 earnings beat and raised 2026 guidance Amgen reported Q2 adjusted EPS of $6.29, well above the $5.62 consensus, and revenue of $10.05 billion, up 10% and ahead of forecasts. Management raised full-year revenue and EPS guidance, signaling confidence in the business. This directly boosts the stock as investors see stronger profits ahead.
This is the main new positive event that drove the stock up over 5% this period.
Key growth drivers show strong momentum Six key products, including Repatha, Evenity, Uplizna, and Imdelltra, grew 26% year-over-year and now make up nearly 70% of product sales. This reduces reliance on older drugs like Enbrel and Otezla, which are facing competition. The shift supports future revenue growth and lifts investor confidence.
It explains the underlying strength behind the earnings beat and why the stock rose.
Cybersecurity breach and class action investigation Amgen disclosed a July cyberattack where sensitive patient and proprietary data was stolen. A law firm has launched a class action investigation. This creates legal and reputational risk, which could weigh on the stock, though Amgen says operations are not materially affected.
It is a new negative event that could pressure the stock and is important for a balanced view.
Obesity drug AMG 513 discontinued; MariTide faces tough competition Amgen ended development of early-stage obesity drug AMG 513, leaving MariTide as its only obesity candidate. MariTide's weight-loss data trails Eli Lilly's and Novo Nordisk's drugs, and switching patients may be hard. This raises doubts about Amgen's ability to compete in the lucrative obesity market.
It is a new setback that could limit future growth and is a key counterweight to the positive earnings.

July 20268 Jul – 23 Jul 2026

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.
This is a major new legal win that directly supports Amgen's revenue outlook.
Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.
New recalls create fresh regulatory and reputational risk that can hurt the stock.
New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.
A new lower-priced competitor directly challenges a key Amgen growth drug.
Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.
New competitive data shows a direct threat to an existing Amgen product.

8 Jul – 23 Jul 2026

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.
This is a major new legal win that directly supports Amgen's revenue outlook.
Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.
New recalls create fresh regulatory and reputational risk that can hurt the stock.
New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.
A new lower-priced competitor directly challenges a key Amgen growth drug.
Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.
New competitive data shows a direct threat to an existing Amgen product.

Q2 202618 Jun – 3 Jul 2026

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.
This is the core positive force behind Amgen's business momentum.
MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.
Pipeline progress is a key driver of long-term growth and investor optimism.
Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.
This is a major negative regulatory event that threatens a marketed drug and investor confidence.
Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.
These are new competitive and legal threats that could weigh on Amgen's stock.

June 202618 Jun – 3 Jul 2026

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.
This is the core positive force behind Amgen's business momentum.
MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.
Pipeline progress is a key driver of long-term growth and investor optimism.
Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.
This is a major negative regulatory event that threatens a marketed drug and investor confidence.
Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.
These are new competitive and legal threats that could weigh on Amgen's stock.

18 Jun – 3 Jul 2026

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.
This is the core positive force behind Amgen's business momentum.
MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.
Pipeline progress is a key driver of long-term growth and investor optimism.
Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.
This is a major negative regulatory event that threatens a marketed drug and investor confidence.
Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.
These are new competitive and legal threats that could weigh on Amgen's stock.